Contrasting effects of sunitinib within in vivo models of metastasis

Sunitinib is a potent and clinically approved tyrosine kinase inhibitor that can suppress tumour growth by inhibiting angiogenesis. However, conflicting data exist regarding the effects of this drug on the growth of metastases in preclinical models. Here we use 4T1 and RENCA tumour cells, which both...

Descripción completa

Detalles Bibliográficos
Autores principales: Welti, Jonathan C., Powles, Thomas, Foo, Shane, Gourlaouen, Morgane, Preece, Natasha, Foster, Julie, Frentzas, Sophia, Bird, Demelza, Sharpe, Kevin, van Weverwijk, Antoinette, Robertson, David, Soffe, Julie, Erler, Janine T., Pili, Roberto, Springer, Caroline J., Mather, Stephen J., Reynolds, Andrew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2012
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496518/
https://www.ncbi.nlm.nih.gov/pubmed/22843200
http://dx.doi.org/10.1007/s10456-012-9291-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496518/
https://www.ncbi.nlm.nih.gov/pubmed/22843200
http://dx.doi.org/10.1007/s10456-012-9291-z

Ejemplares similares